Dove期刊
期刊
会议
图书
作者:Shirish Gadgeel , Amy Weise
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.35-42Dove
摘要:Abstract:Non-small cell lung cancer is a heterogeneous disease and a challenging malignancy to treat as many patients have advanced disease at the time of diagnosis. Recent advances have led to the identification of molecularly defined subtypes of NSCLC, namely for patients with ...
作者:Federico Cappuzzo , Irene Stasi
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.43-50Dove
摘要:Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidilserine (PS) expressed on tumor endothelium, with a unique mechanism of action. PS is an anionic membrane phospholipid, normally restricted to the inner membran...
作者:Sacha Rothschild
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.51-57Dove
摘要:The therapeutic landscape in non-small cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so called oncogenic driver mutations) and the development of targeted agents interfering with the tumor promoting...
作者:Sana Karam , David Duhamel , Zachary Horne ...
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.59-66Dove
摘要:OBJECTIVE: In elderly patients with Stage IIB-IV non small cell lung cancer (NSCLC) who cannot tolerate chemotherapy, conventionally fractionated radiotherapy is the treatment of choice. We present our experience with hypofractionated Stereotactic Body Radiation Therapy (SBRT) in...
作者:Takahiro Nakajima , Ichiro Yoshino , Terunaga Inage
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.67-72Dove
摘要:Accurate staging is the first step for management of lung cancer. Nodal staging is quite important for physicians to judge primary operability of patients harboring no distant metastasis. For many years, mediastinoscopy has been considered to be a “gold standard” modality fo...
作者:Niki Karachaliou , Rafael Rosell
来源:[J].Lung Cancer: Targets and Therapy, 2014, Vol.2014 (default), pp.73-79Dove
摘要:Deeper understanding of the pathobiology of NSCLC has led to the development of small molecules that target genetic mutations known to play critical roles in progression to metastatic disease. The discovery of EGFR mutations in 15–20% of lung adenocarcinomas and the associat...
作者:Baofa Yu , Chenglin Sun , Peichang Zhang ...
来源:[J].Lung Cancer: Targets and Therapy, 2015, Vol.2015 (default), pp.1-11Dove
摘要:Aims: To evaluate the therapeutic effects of hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by UMIPIC and to analyze the effect of this immune booster.Materials and Methods: Ninety seven patients with advanced lung cancers were treated with UMIPIC or ...
作者:Seigo Minami , Takashi Kijima
来源:[J].Lung Cancer: Targets and Therapy, 2015, Vol.2015 (default), pp.13-25Dove
摘要:Pemetrexed, a multi-targeting anti-folate cytotoxic drug, plays a leading role of front-line chemotherapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC), owing to its powerful anti-tumor effects and mild toxicities. Following the approval as the second...
作者:Trever Bivona , Ross Okimoto
来源:[J].Lung Cancer: Targets and Therapy, 2015, Vol.2015 (default), pp.27-34Dove
摘要:The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and EMT associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer and targe...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×